載入...
2227. Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients
BACKGROUND: Short-duration with an 8-week course of ledipasvir/sofosbuvir (LDV/SOF) or glecaprevir/pibrentasvir (GLE/PIB) is considered adequate to treat hepatitis C virus (HCV) infection in selected patients. However, immunocompromised patients with HCV/HIV are not eligible for this approach. Herei...
Na minha lista:
| 發表在: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6253132/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1880 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|